
Nuvation Bio (NUVB) Stock Forecast & Price Target
Nuvation Bio (NUVB) Analyst Ratings
Bulls say
Nuvation Bio is primed for success with a diversified and promising pipeline, a strong financial position with $533.7MM in cash and cash equivalents, and a growing presence in the biopharmaceutical industry as seen through their acquisition of safusidenib rights from DaiichiSankyo. The company's future success will be heavily dependent on the commercial launch of its flagship drug Ibtrozi and the successful development of safusidenib, with potential risks including delays in clinical trial enrollment and increased competition from other biopharmaceutical companies.
Bears say
Nuvation Bio is facing several challenges that are likely to impact its financial performance, including lower-than-expected revenue from its product, taletrectinib, due to the lumpy revenue dynamics of an early-stage oncology launch and the limited market size for ROS1+ NSCLC. The company's decision to pursue all grades and types of glioma with its other product, Safusidenib, may lead to increased research and development costs, which could impact profitability in the short term. Additionally, the company's reliance on out-licensing collaborative agreements for revenue generation leaves it vulnerable to any changes in its partners' financial stability or strategic priorities.
This aggregate rating is based on analysts' research of Nuvation Bio and is not a guaranteed prediction by Public.com or investment advice.
Nuvation Bio (NUVB) Analyst Forecast & Price Prediction
Start investing in Nuvation Bio (NUVB)
Order type
Buy in
Order amount
Est. shares
0 shares